View Older Stories View More Recent Stories
-
Leerink Partners Upgrades Regeneron Pharma (REGN) to Outperform
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
Regeneron Pharma (REGN) PT Lowered to $1,150 at Morgan Stanley
-
Regeneron (REGN) Tops Q4 EPS by 80c
-
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
DEADLINE REMINDER: Berger Montague Reminds Regeneron Pharmaceuticals, Inc. (REGN) Investors of Important Class Action Lawsuit Deadline
-
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
ATTENTION REGENERON PHARMACEUTICALS, INC. (REGN) Shareholders: Securities Fraud Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
-
Regeneron Pharma (REGN) PT Lowered to $1,000 as Bernstein 'Expects EPS Miss Given Today's Dupixent Results'
-
ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
-
ROSEN, A TOP-RANKED LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
Regeneron Pharma (REGN) PT Lowered to $1,030 at TD Cowen
-
Regeneron Pharmaceuticals (REGN) Investor Alert: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
Regeneron Pharma (REGN) PT Lowered to $762 at Leerink Partners
-
ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
Regeneron Pharma (REGN) PT Lowered to $1,013 at Piper Sandler as Eylea HD Revenue Misses Consensus
-
CLASS ACTION REMINDER: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Lawsuit by March 10, 2025
-
ROSEN, A TOP-RANKED LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
REGN CLASS ACTION NOTICE: Berger Montague Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire About a Securities Fraud Class Action
-
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)- Hagens Berman
-
SHAREHOLDER ALERT: Berger Montague Reminds Regeneron Pharmaceuticals (NASDAQ: REGN) Investors of a Class Action Lawsuit Deadline
-
REGENERON PHARMACEUTICALS SECURITIES FRAUD NOTICE: Berger Montague Informs Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of Securities Fraud Lawsuit
-
ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
-
ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
UBS Downgrades Regeneron Pharma (REGN) to Neutral
-
Bernstein Reiterates Outperform Rating on Regeneron Pharma (REGN) Following a Sell-side Q&A
-
Regeneron Pharmaceuticals, Inc. (REGN) Securities Fraud: Contact Berger Montague To Discuss Your Rights
-
Goldman Sachs Reiterates Buy Rating on Regeneron Pharma (REGN)
-
Regeneron Pharma (REGN) PT Lowered to $1,120 at Jefferies
-
Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN)
-
Regeneron (REGN) Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
-
Regeneron (REGN) Reports Adjuvant Libtayo Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
-
Regeneron (REGN) Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare D

